Company’s New Groundbreaking Preclinical Data in NSCLC Models Provides Further Validation for SIL204's Innovative Delivery ...

Revolution Medicines Inc. (NASDAQ:RVMD) is one of the most promising stocks according to Wall Street analysts. On June 23, ...

The published data showed that the combination of avutometinib plus defactinib demonstrated a confirmed overall response rate of 31% in all patients with recurrent low-grade serous ovarian cancer ...

Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term growth. Learn why VSTM stock is a buy.

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer. Share.

Scientists at Fox Chase Cancer Center have identified a mutation in a common oncogene—a gene that can cause cancer—that may play an important role in colon cancer. Researchers also showed how this ...

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with ...

These findings highlight the dual roles of antioxidants in cancer. Their impact depends on cancer type, stage, and genetic ...

For decades, cancers with mutations in the gene KRAS (KAY-ras) were considered “undruggable.” KRAS mutations are found in more than 20% of cancers.They are most common in lung cancer, pancreatic ...

RAMP 203 (NCT05074810) is a Phase 1/2, multicenter, open-label, dose evaluation/expansion study, being conducted in collaboration with Amgen, evaluating the efficacy and safety of avutometinib and ...